Global point of care
Diabetes is one of the biggest global public health concerns and continues to rise in prevalence. The International Diabetes Federation (IDF), says that, as of 2021, 537 million adults 20-79 years old are living with diabetes worldwide. That’s the same as 1 in 10 people. Unfortunately, this number is set to rise to 643 million by 2030 and 783 million by 2045.1
Significantly, diabetes is a condition that can remain undiagnosed, sometimes for years. Almost one in two adults with diabetes remains undiagnosed.1 Type 2 diabetes makes up most of these cases. With clear links to comorbidities, such as cardiovascular disease, renal disease, nephropathy, and eye problems, diabetes is a growing burden on patients and healthcare systems globally.
We’re changing disease management around the globe. We can help you and your staff manage diabetes in your patients with better outcomes for everyone.
With the high rates of diabetes globally, and large groups of undiagnosed prediabetic patients it's likely you, as a primary care professional, encounter it every day.
Testing, treatment, and compliance are the most effective ways to address diabetes. But, of course, these first rely on a diagnosis.
From the physician’s office to point-of-care sites in hospitals, rapid, reliable HbA1c testing helps to provide the clinical care that patients deserve. When patients have their tests and results on their first visit, they can manage prediabetes or diabetes more effectively.
Point-of-care testing enhances clinical efficiencies in busy practices and can help to stem the massive economic impact of diabetes around the world.
Point of care (POC) HbA1c testing allows for accurate test results, diagnosis, and diabetes management counseling. Where central laboratory testing can take days before results are back, rapid diagnostics provide results in minutes.
With HbA1c point-of-care testing results on hand, you can create immediate coachable moments with your patients and educate them on their condition, empower them to take part in their own care, and adapt their treatment as required, without the need to bring them back for another consultation.
Studies show that patients who test in compliance with ADA guidelines are over five times more likely to achieve a recommended HbA1c under 7% than those who do not.4 HbA1c testing at the point of care makes it easy and convenient for patients to be tested regularly since it only takes a few minutes and no extra lab visits or follow-ups are needed.
Patients are also more likely to test regularly when it’s quick and convenient for them. A minimally invasive finger stick blood sample is less time-consuming and less painful when compared to venous blood draw.4 It is also suitable for children and the elderly and individuals who are averse to needles.
Research has shown that there are links between the immediacy of point-of-care results, patient motivation to be aware of their condition, and long-term adherence to guideline recommendations.5
Studies show that patients who test in compliance with ADA guidelines are over five times more likely to achieve a recommended HbA1c under 7% than those who do not4. HbA1c testing at the point of care makes it easy and convenient for patients to be tested regularly since it only takes a few minutes and no extra lab visits or follow-ups are needed.
Patients are also more likely to test regularly when it’s quick and convenient for them. A minimally invasive finger stick blood sample is less time-consuming and less painful when compared to venous blood draw.4 It is also suitable for children and the elderly and individuals who are averse to needles.
Research has shown that there are links between the immediacy of point-of-care results, patient motivation to be aware of their condition, and long-term adherence to guideline recommendations.5
With its compact size and panel of tests, the Afinion 2 System is ideal for POC testing in physician offices, clinics, community health centers, retirement homes, emergency rooms, and hospital outpatient clinics.
The Afinion 2 Analyzer provides accurate lab-quality6 results, so the right treatment plan can be implemented with confidence. Certified by NGSP and IFCC the Afinion 2 Analyzer showed excellent results in an independent performance study from the European Reference Laboratory for Glycohemoglobin.8
The Afinion™ 2 analyzer is a compact, rapid, multi-assay analyzer that provides valuable near patient testing at the point-of-care. With the Afinion™ System, there’s no need to send test results to the lab or spend time tracking them down.
Test for quantitative determination of glycated hemoglobin (HbA1c) in human whole blood, used to monitor metabolic control in patients with diabetes.
A LEADER IN RAPID POINT-OF-CARE DIAGNOSTICS.
©2024 Abbott. All rights reserved. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.
Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy. Photos displayed are for illustrative purposes only. Any person depicted in such photographs is a model. GDPR Statement.
Not all products are available in all regions. Check with your local representative for availability in specific markets. For in vitro diagnostic use only. For i-STAT test cartridge information and intended use, refer to individual product pages or the cartridge information (CTI/IFU) in the i-STAT Support area.
Abbott - A Leader in Rapid Point-of-Care Diagnostics.
